Our study indicated that epalrestat, an aldose reductase inhibitor, effectively suppressed NLRP3 inflammasome activation in vivo and in vitro and might be a new therapeutic approach for NASH. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.